arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

HERON THERAPEUTICS, INC. /DE/

HRTX
$0.49 ▼ -0.01 (-1.91%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

HERON THERAPEUTICS, INC. /DE/ faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $92.9M
Dividend Yield
Revenue Growth -10.8%
Op. Margin -13.7%
ROIC -41.2%
FCF / Share $-0.01
Trailing P/E
Price / Book 10.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$34.71M
↓ -10.8%
Net Income Profit after all expenses
$-8.11M
↓ -174.6%
Operating Margin Operating profit as % of sales
-13.7%
↓ -28.2% 25th
FCF / Share Free cash flow per share
$-0.01
↑ +82.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
16
Returns
5
Financial Health
47
Cash Quality
78

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters